NCT00394082 - ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2006

Primary Completion Date

September 1, 2009

Study Completion Date

February 1, 2011

Conditions

Metastatic Breast Cancer

Interventions

DRUG

ABI-007

125 mg/m\^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.

DRUG

Bevacizumab

Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.

Trial Locations (20)

14623

Rochester

21044

Columbia

21157

Westminister

22031

Fairfax

23502

Norfolk

24153

Salem

32901

Melbourne

34761

Ocoee

47802

Terre Haute

60714

Niles

64507

Saint Joseph

75246

Dallas

75702

Tyler

76022

Bedford

78229

San Antonio

79761

Odessa

79915

El Paso

98026

Edmonds

98166

Burien

98684

Vancouver